Trial Profile

A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients With Relapsed or Refractory Disease.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Romidepsin (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Sponsors Celgene Corporation

Most Recent Events

27 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
03 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
18 Nov 2009 Planned end date changed from 1 Nov 2009 to 1 Apr 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com